IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients.
Roberti MP, Rocca YS, Amat M, Pampena MB, Loza J, Coló F, Fabiano V, Loza CM, Arriaga JM, Bianchini M, Barrio MM, Bravo AI, Domenichini E, Chacón R, Mordoh J, Levy EM.
Roberti MP, et al. Among authors: mordoh j.
Breast Cancer Res Treat. 2012 Dec;136(3):659-71. doi: 10.1007/s10549-012-2287-y. Epub 2012 Oct 14.
Breast Cancer Res Treat. 2012.
PMID: 23065032